Showing results (31-40 of 97) with videos related to
Sort By:
Pageof 10
British Journal of Haematology|July 24, 2015
Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II studyPeter M Voorhees, Robert Z Orlowski, Flora Mulkey, et al.Palliative & Supportive Care|March 8, 2017
A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer painChristine Rini, Maihan B Vu, Hannah Lerner, et al.Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With DaratumumabDonald C Moore, Justin R Arnall, Daniel L Thompson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myelomaPeter M Voorhees, Qing Chen, Deborah J Kuhn, et al.American Journal of Hematology|June 27, 2024
Hereditary chronic neutrophilic leukemia in a four-generation family without transformation to acute leukemiaAmanda Lance, Zane Chiad, Sara L Seegers, et al.Clinical Lymphoma, Myeloma & Leukemia|April 14, 2020
Safety and Cost Benefits of the Rapid Daratumumab Infusion ProtocolIssam S Hamadeh, Emily S Reese, Justin R Arnall, et al.Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical PracticeIssam S Hamadeh, Donald C Moore, Allison Martin, et al.Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.Clinical Lymphoma, Myeloma & Leukemia|November 28, 2022
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple MyelomaDavid M Foureau, Barry A Paul, Fei Guo, et al.Pageof 10